SCHEMBL3757693

SCHEMBL3757693

CC(C)(O)C(C)(C)OB(O)c1cccc(CN2CCCCC2)c1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
GAA P10253 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
CYP2D6 P10635 2/20 0.44
CYP2C9 P11712 1/20 0.44
HIF1A Q16665 1/20 0.44
PRMT6 Q96LA8 1/20 0.43
CYP2C19 P33261 1/20 0.38
MBTD1 Q05BQ5 1/20 0.38
TP53BP1 Q12888 1/20 0.38
L3MBTL3 Q96JM7 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1851425 0.99 ALDH1A1 (0.44) ALDH1A1KDM4EGAASMN1; SMN2TDP1
SCHEMBL2509532 0.89 MC4R (0.44) ALDH1A1KDM4ETDP1PRMT6HRH3
SCHEMBL12802187 0.88 NCF1 (0.47) ALDH1A1KDM4ESMN1; SMN2HRH3
Hydrochloric Acid SCHEMBL3328959 0.87 NCF1 (0.46) ALDH1A1KDM4ESMN1; SMN2HRH3
SCHEMBL6698475 0.79 ENPP2 (0.53)
SCHEMBL3135413 0.78 ENPP2 (0.37)
SCHEMBL3036815 0.78 ENPP2 (0.39) ALDH1A1SMN1; SMN2
SCHEMBL18580532 0.77 ALDH1A1 (0.39) ALDH1A1KDM4EGAAPRMT6L3MBTL3
SCHEMBL29955283 0.77 SMN1; SMN2 (0.63) ALDH1A1KDM4EGAASMN1; SMN2TDP1
SCHEMBL2248354 0.77 SMN1; SMN2 (0.63) ALDH1A1KDM4EGAASMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA ALDH1A1 3061/4885KDM4E 1014/4885GAA 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.